The Journal of Allergy and Clinical Immunology: In Practice
Original articleHigh Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma
Section snippets
PREDUNA study protocol
The PREDUNA study was a retrospective cohort study that examined the relationship between the blood eosinophil count at baseline (2010) and asthma exacerbations in the following 12 months (2011). The study used the Kaiser Permanente Southern California (KPSC) research data warehouse to capture pharmacy and health care utilization data to identify patients with persistent asthma and to determine asthma-related outcomes (Figure 1, A). The KPSC Institutional Review Board approved the study with a
Identification of patients with persistent asthma
When applying HEDIS criteria for persistent asthma, 71,780 and 70,661 patients of all ages with persistent asthma were identified in 2009 and 2010, respectively, with 55% (n = 39,138) fulfilling the 2-year definition of persistent asthma (Figure 1, B). After exclusion of patients due to noncontinuous membership or pharmacy benefit, age limitation, and specific diseases, 9546 adults 18 to 64 years of age with persistent asthma were identified, with 2392 (25.1%) having had at least 1 blood cell
Discussion
Eosinophilia in blood (tissues also) is a biologic inflammatory marker that links asthma to a specific pathophysiologic phenotype3, 4, 5, 35 and responsiveness to specific medications.15, 16, 17, 18, 36 The PREDUNA study provides evidence that high blood eosinophil counts of adults with persistent asthma are associated with increased risk for future asthma exacerbations and excessive SABA canisters dispensed after adjustments for covariates. High blood eosinophil count was hypothesized as a
References (56)
- et al.
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal
J Allergy Clin Immunol
(2001) - et al.
Phenotypic predictors of response to oral glucocorticosteroids in severe asthma
Respir Med
(2013) - et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
(2005) - et al.
The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes
Chest
(2006) - et al.
Asthma quality-of-care measures using administrative data: relationships to subsequent exacerbations in multiple databases
Ann Allergy Asthma Immunol
(2008) - et al.
Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data
J Allergy Clin Immunol
(2006) - et al.
Short-acting beta-agonist prescription fills as a marker for asthma morbidity
Chest
(2005) - et al.
Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations
Ann Allergy Asthma Immunol
(2008) - et al.
Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids
J Allergy Clin Immunol
(2011) - et al.
Blood eosinophils and eosinophil-derived proteins in allergic asthma
J Allergy Clin Immunol
(1989)
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial
J Allergy Clin Immunol
Severe adult-onset asthma: a distinct phenotype
J Allergy Clin Immunol
High blood eosinophil count is associated with more frequent asthma attacks in asthma patients
Ann Allergy Asthma Immunol
Improving asthma outcomes in large populations
J Allergy Clin Immunol
Overweight/obesity and risk of seasonal asthma exacerbations
J Allergy Clin Immunol Pract
Asthma quality-of-care markers using administrative data
Chest
Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology
J Allergy Clin Immunol
FEV(1) is associated with risk of asthma attacks in a pediatric population
J Allergy Clin Immunol
Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children
J Allergy Clin Immunol
Biomarkers of eosinophilic inflammation in asthma
Expert Rev Respir Med
Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions
Clin Allergy
Age-dependent interaction between atopy and eosinophils in asthma cases: results from NHANES 2005-2006
Clin Exp Allergy
Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing
Clin Exp Allergy
Importance of concomitant local and systemic eosinophilia in uncontrolled asthma
Eur Respir J
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program
Am J Respir Crit Care Med
Childhood asthma clusters and response to therapy in clinical trials
J Allergy Clin Immunol
Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis
J Allergy Clin Immunol
Cited by (0)
MedImmune, Gaithersburg, Md, funded a research grant to the Southern California Permanente Medical Group Research and Evaluation Department to perform the study. The sponsor participated in the study discussions and provided comments to the protocol, data analysis, and manuscript.
Conflicts of interest: R. Zeiger has received research support from MedImmune, Genentech, GlaxoSmithKline, Aerocrine, Merck, Thermofisher, and AstraZeneca; was on the DBV Technologies research advisory board; has received consultancy fees from GlaxoSmithKline, Genentech, Novartis, the National Heart, Lung, and Blood Institute/Penn State, and Aerocrine; and holds stock/stock options in DBV Technologies. M. Schatz has received research support from MedImmune. Q. Li has received research support from AstraZeneca. W. Chen has received research support from Kaiser Permanente Southern California. D. Khatry is employed by MedImmune/AstraZeneca; has a pending patent with MedImmune; has stock/stock options in MedImmune/AstraZeneca. D. Gossage is employed by Gilead Sciences; has a patent with MedImmune/AstraZeneca; has stock in Gilead Sciences Inc. T. N. Tran is employed by and has stock/stock options in AstraZeneca.